Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Radioligand therapy for mCRPC

Thomas Hope • 13 Feb 2020
GU Cancers 2020
Genitourinary Cancer Prostate Cancer
VISION

Thomas Hope, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the use of radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Dr Hope specifically highlights the VISION trial (NCT03511664), which is investigating the use of 177Lu-PSMA-617 in this patient population. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Thomas Hope

2:13
Prostate cancer imaging: challenging cases
Thomas Hope • 13 Feb 2020
0:55
Prostate cancer: role of the radiologist
Thomas Hope • 13 Feb 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals